DMAC insider transaction filings
DiaMedica Therapeutics Inc. — 31 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen DMAC transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | Pauls Dietrich John — President & CEO, Director | Grant/award (A): 60,200 @ $0 | EDGAR |
| 2026-06-03 | 4 | Semba Charles Pauling — Director | Grant/award (A): 40,412 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Pauls Dietrich John — President & CEO, Director | Grant/award (A): 380,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Parsons James T. — Director | Grant/award (A): 51,189 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Giuffre Randall Michael — Director | Grant/award (A): 40,412 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Krop Julie — Chief Medical Officer | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Kellen Scott — CFO & Secretary | Grant/award (A): 162,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Lewis Tanya — Director | Grant/award (A): 40,412 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | O'Connor Daniel J. — Director | Grant/award (A): 40,412 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Kuntz Richard — Director | Grant/award (A): 40,412 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Semba Charles Pauling — Director | Grant/award (A): 3,355 @ $8.42 | EDGAR |
| 2026-01-06 | 4 | Parsons James T. — Director | Grant/award (A): 10,095 @ $8.42 | EDGAR |
| 2026-01-06 | 4 | Giuffre Randall Michael — Director | Grant/award (A): 6,175 @ $8.42 | EDGAR |
| 2025-12-08 | 4 | STAHLBERG JAN — 10% owner TRILL AB — 10% owner | Purchase (P): 187,393 @ $6.52 · Purchase (P): 182,882 @ $6.75 · Purchase (P): 240,352 @ $7.21 · Purchase (P): 128,426 @ $7.41 · Purchase (P): 208,872 @ $7.41 · Purchase (P): 40,253 @ $7.89 · +1 more | EDGAR |
| 2025-11-25 | 4 | Parsons James T. — Director | Option exercise (M): 12,000 @ $2.20 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | Krop Julie — Chief Marketing Officer | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | STAHLBERG JAN — 10% owner TRILL AB — 10% owner | Purchase (P): 293,601 @ $5.91 · Purchase (P): 70,414 @ $5.99 · Purchase (P): 8,233 @ $6 · Purchase (P): 71,107 @ $5.86 · Purchase (P): 48,172 @ $5.96 · Purchase (P): 59,788 @ $5.96 · +3 more | EDGAR |
| 2025-07-25 | 4 | STAHLBERG JAN — 10% owner TRILL AB — 10% owner | Purchase (P): 1,542,857 @ $3.50 | EDGAR |
| 2025-07-25 | 4 | Von Koch Thomas — 10% owner TomEnterprise AB — 10% owner TomEnterprise Private AB — 10% owner | Purchase (P): 2,857,142 @ $3.50 | EDGAR |
| 2025-07-25 | 4 | JACINTO RICHARD II — 10% owner | Purchase (P): 400,000 @ $3.50 | EDGAR |
| 2025-06-03 | 4 | Wambeke David J. — Chief Business Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Semba Charles Pauling — Director | Grant/award (A): 32,162 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Pauls Dietrich John — President & CEO, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Parsons James T. — Director | Grant/award (A): 40,739 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Lewis Tanya — Director | Grant/award (A): 32,162 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Kellen Scott — CFO & Secretary | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Giuffre Randall Michael — Director | Grant/award (A): 32,162 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Kuntz Richard — Director | Grant/award (A): 32,162 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | Pilnik Richard D. — Director | Option exercise (M): 24,000 @ $2.11 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | O'Connor Daniel J. — Director | Grant/award (A): 64,242 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Giuffre Randall Michael — Director | Option exercise (M): 12,000 @ $2.11 · Option exercise (M): 5,000 @ $3.65 · Option exercise (M): 12,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — DiaMedica Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-05 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DMAC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →